Interstitial lung diseases (ILDs) represent a heterogeneous group of disorders characterized by inflammation and fibrosis of the pulmonary parenchyma. These disorders, often complex and challenging, require a comprehensive understanding for appropriate diagnosis and management.
ILDs can be idiopathic or associated with systemic diseases, environmental exposures, or drugs. The most common idiopathic form is idiopathic pulmonary fibrosis (IPF). Other forms include connective tissue disease-associated ILD, hypersensitivity pneumonitis, and drug-induced ILD. Classifying ILDs is crucial for prognosis and management.
Patients typically present with progressive dyspnea and non-productive cough. The physical examination may reveal inspiratory crackles and finger clubbing. High-resolution computed tomography (HRCT) is the cornerstone for diagnosis, often showing reticular opacities and honeycombing. Pulmonary function tests reveal a restrictive pattern with reduced diffusing capacity. Bronchoalveolar lavage and lung biopsy may be used in certain cases.
Management strategies depend on the underlying cause. For IPF, antifibrotic agents such as pirfenidone and nintedanib are recommended. In connective tissue disease-associated ILD, immunosuppressive therapy is often beneficial. Lung transplantation may be considered for select patients with advanced disease. All patients should receive supportive care, including pulmonary rehabilitation and oxygen therapy if needed.
The prognosis varies widely among ILDs. IPF has a poor prognosis with a median survival of 2-3 years from diagnosis. Meanwhile, other ILDs such as those associated with connective tissue diseases may have a more indolent course. Early diagnosis and appropriate management can improve the quality of life and potentially slow disease progression.
Understanding ILDs requires a comprehensive approach encompassing a thorough history, appropriate diagnostic tests, and a nuanced treatment plan. As healthcare professionals, staying informed about advances in the field is crucial to provide optimal care for patients living with these complex disorders.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation